Mirae Asset Global ETFs Holdings’s Cytokinetics CYTK Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.02M	Buy	61,177 +1,542	+3%	+$98K	0.01%	881
2025 Q4	$3.78M	Buy	59,635 +143	+0.2%	+$8.9K	0.01%	897
2025 Q3	$3.26M	Sell	59,492 -12,818	-18%	-$528K	0.01%	944
2025 Q2	$2.39M	Sell	72,310 -2,608	-3%	-$90.7K	﹤0.01%	1016
2025 Q1	$3.03M	Buy	74,918 +3,260	+5%	+$150K	0.01%	927
2024 Q4	$3.37M	Buy	71,658 +659	+0.9%	+$34.2K	0.01%	888
2024 Q3	$3.74M	Buy	70,999 +7,340	+12%	+$409K	0.01%	862
2024 Q2	$3.45M	Buy	+63,659	New	+$3.84M	0.01%	875

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CYTK Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Cytokinetics (CYTK) stake by 2.6% in Q1 2026, buying an estimated $98K and bringing the position to 61,177 shares worth $4.02M. The position accounts for 0.01% of the portfolio, ranked #881.

Mirae Asset Global ETFs Holdings first reported a position in CYTK in Q2 2024 and has held it in 8 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Mirae Asset Global ETFs Holdings held 61,177 shares of Cytokinetics worth $4.02M as of Q1 2026.
Mirae Asset Global ETFs Holdings bought 1,542 Cytokinetics shares in Q1 2026, an estimated $98K.
Cytokinetics made up 0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #881 holding.
Mirae Asset Global ETFs Holdings first reported a position in Cytokinetics in Q2 2024 and has held it in 8 quarters since.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.